US drug prices post steepest annual decline in decades as GLP-1 competition adds pressure

Prescription drug prices in the US fell 0.8% in July 2026 and are down 3.1% from a year earlier — the steepest annual decline in more than six decades, according to Consumer Price Index data ^[1]. An Axios analysis of the July figures concluded that TrumpRx, the administration's site connecting patients with discounted cash prices for certain drugs, likely accounts for only part of the drop, pointing also to Medicare price negotiations, patent expirations and generic entry, and price cutting in the GLP-1 class ^[1].

Prices have not risen in any month this year ^[1]. The broader medical care commodities category, which includes prescription and nonprescription drugs plus medical equipment and supplies, fell 2.7% over the previous 12 months ^[2]. Costs for hospital and physician services kept rising over the same period ^[1].

What is driving the decline

Eli Lilly and Novo Nordisk struck deals with the administration that cut cash prices for their blockbuster GLP-1 drugs and expanded Medicare access ^[1]. Heated competition in the GLP-1 market is pushing down cash-pay prices, and those cuts may have added to broader downward pressure, though other forces were already at work ^[1].

Medicare negotiated prices established under the Inflation Reduction Act took effect in January for 10 of the program's costliest drugs, with negotiated prices as much as 79% below their list prices ^[1]. Patent expirations and cheaper generics entering the market added further pressure, a shift the government's inflation gauge is designed to capture ^[1].

Geoffrey Joyce, a health economist at USC, said TrumpRx mostly makes existing discounts easier to find. "If you were going to give policy credit, you'd have to say the IRA," he said, adding that much of the decline is being driven by market forces ^[1].

The White House disputes that framing. Spokesperson Kush Desai called attributing the decline to the IRA "idiotic and unfounded," arguing that its negotiated prices failed to deliver meaningful savings beyond existing insurer discounts, and pointed instead to most-favored-nation deals aimed at aligning US prices with lower prices overseas, plus TrumpRx discounts ^[1]. The administration's Council of Economic Advisers has estimated that MFN pricing commitments could generate about $529 billion in US savings over 10 years ^[2]. STAT reported that the details of the agreements have not been fully disclosed, which makes independent evaluation of their effect on spending difficult ^[2].

The CPI itself does not determine causes ^[2]. The Bureau of Labor Statistics told Axios that the index tracks the prices pharmacies receive from patients and insurers, including Medicare, not just what consumers pay out of pocket, and that manufacturer rebates paid after the transaction are not captured ^[1].

Why it matters for patients

A falling national index does not guarantee that any individual patient pays less. The effect on a given person may vary based on insurance coverage, the medication, the pharmacy, and access to alternative discounts or generic products ^[2]. KFF found that TrumpRx may provide meaningful discounts for some consumers, particularly those paying cash, but noted that people with insurance may sometimes get lower prices through their health plan or a manufacturer assistance program, and that generic alternatives were available for some listed medications and could sometimes be bought at lower prices elsewhere ^[2].

Joyce said patients focus on their own share of the bill. "People don't care about what the true cost of the drug is," he said. "They just say, 'What's my copay?' or 'What's my cost sharing at the pharmacy counter?'" ^[1]

Surveys reflect that gap. Six in 10 Americans said this spring they were worried about affording their medications — the largest share since KFF began tracking the question in 2018 — and 4 in 10 said they had not taken medication as prescribed in the past year because of cost ^[1].

What happens next

How much each factor — most-favored-nation agreements, TrumpRx, Medicare negotiation, generics and GLP-1 competition — contributes to the decline has not been established ^[2]. Determining whether the savings persist and how broadly they reach insured and uninsured patients will require additional data as the policies are implemented ^[2]. No further detail on the timing or scope of upcoming pricing changes has been disclosed ^[1][2].